AbbVie's Etentamig Clears Phase 3 Myeloma Trial on Both Endpoints & GSK Pays HUTCHMED $110M Upfront for KRAS-EGFR Drug

AbbVie's BCMA x CD3 bispecific etentamig met both primary endpoints in the Phase 3 CERVINO myeloma study — a 74.0% response rate versus 45.7% for standard therapy and a 60% reduction in the risk of progression or death — with a safety profile AbbVie is positioning for outpatient and community care. GSK is paying HUTCHMED $110 million upfront — up to $1.295 billion in total — for HMPL-A830, a dual KRAS/EGFR antibody-targeted conjugate whose global Phase 1 hasn't started yet. Also: the FDA approved Ionis' Zanvastro (zilganersen), the first treatment for Alexander disease, two weeks ahead of its PDUFA date. Plus Gan & Lee licenses bofanglutide (GZR18) to Menarini across 39 European countries (EUR 62M upfront, up to EUR 726M total), and Cipla partners with Qilu on QL2107, a Keytruda (pembrolizumab) biosimilar for the US.

Alex Mercer and Maya Patel host the Daily Roundup for September 3. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.